Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis-Reference-Cited by-同舟云学术

Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis

Published:2017-08-22 Issue:10 Volume:10 Page:1037-1047
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Osherov Michael¹,Milo Ron¹^ORCID

Affiliation:

1. Department of Neurology, Barzilai University Medical Center, Ashkelon, Faculty of Health Sciences, Ben-Gurion University of the Negev, Ashkelon, Israel

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2017.1366854

Reference52 articles.

1. Multiple sclerosis

2. Multiple sclerosis: Geoepidemiology, genetics and the environment

3. Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

4. Daclizumab Therapy for Multiple Sclerosis

5. The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies;Clinical Microbiology Reviews;2020-06-17

2. Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice;Clinical Therapeutics;2018-06

3. Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases;Clinical Genetics;2018-02-27